Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product Jan 14, 2022
Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted… Jan 13, 2022
How Significant Are Recent Changes To Psychedelics Access In Canada? ‘It Can’t Be Understated’ Says Numinus CEO Jan 12, 2022
MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia Jan 12, 2022
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program Jan 12, 2022
